Come to Market Access World USA 2011 and learn:
•How new reimbursement models will impact market access
•How CER will differ from EU HTA experience
•What is the role of real life/observational studies in the future security of market access
•HTA agency policy and practice globally: comparing and contrasting different models
•Risk sharing, value based pricing, pay for performance
•Quality improvement measures

Speakers include:
Kelly Whitener
Health Policy Advisor
Majority Staff
Senate Finance Committee

Executive Director, Division
of New Health Technology
Assessment
National Evidence-based
Healthcare Collaborating
Agency (NECA), South Korea

Marcus Wilson
President
Healthcare

John J. Kaelin, Senior Vice
President, State Program
Development
UnitedHealth Group

Naomi Aronson
Executive Director, Office of
Clinical Affairs – Technology
Evaluation Center (TEC)
BlueCross BlueShield
Association

Chip Davis, Executive Vice
President Advocacy, PhRMA

Eric Klein, Head of Global HTA and
Outcomes, Eli Lilly

Dr Michael Lauer, Director,
Division of Cardiovascular
Sciences, NIH
And many more

Prices start at $1790